A closer look at why a cannabis operator listed in Canada just recruited one of the most recognisable names in U.S. exchange infrastructure.
The Cresco Labs board appointment announced on September 17, 2026 hands one of the most recognisable names in U.S. exchange infrastructure a seat at a cannabis operator’s table. Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) said Edward Tilly, the former chairman and chief executive of CBOE Global Markets, will join its Board of Directors effective September 18, 2026, serving as an independent director and sitting on the Audit Committee.
The addition brings the board to eight directors. For a company whose shares trade on the Canadian Securities Exchange while its operations sit entirely inside the United States, the choice of a career markets executive over another operator or brand specialist is the detail worth reading twice.
An Independent Seat and a Spot on the Audit Committee
Cresco Labs framed the move around governance rather than operations. Tilly comes in as an independent director, meaning he is not part of management, and he goes directly onto the Audit Committee — the committee responsible for overseeing financial reporting, external auditors and internal controls.
Here is the appointment at a glance, based strictly on what the company disclosed:
| Appointee | Edward Tilly |
| Role | Independent director |
| Committee | Audit Committee |
| Effective date | September 18, 2026 |
| Board size after appointment | Eight directors |
| Announcement date | September 17, 2026 |
| Listings | CSE: CL | OTCQX: CRLBF | FSE: 6CQ |
No committee chairmanship, term length or director compensation arrangement was disclosed in the announcement.
Edward Tilly’s Decade Running CBOE Global Markets
Tilly’s résumé runs more than 35 years across exchange operations, market structure, capital markets and regulatory engagement. He spent a decade as chairman and chief executive of CBOE Global Markets, a period in which the business moved from being a domestic options exchange to a diversified global market infrastructure operator.
The scale of that shift is measurable. Cresco Labs said CBOE’s market capitalisation grew from roughly US$2 billion to more than US$18 billion during his tenure, and that he led the company’s US$3.4 billion acquisition of BATS Global Markets. Under his leadership CBOE’s operational footprint expanded to six continents.
Those are the credentials of someone who has spent a career on the plumbing side of finance — clearing, listings, trading venues and the rules that govern them — rather than on the consumer-brand side of the business Cresco actually runs.
From the World Federation of Exchanges to Clear Street
Tilly served as chairman of the World Federation of Exchanges from 2021 to 2023, the global industry body for regulated exchanges and clearing houses. He has also held board seats at the Options Clearing Corporation and the National Stock Exchange.
Most recently he was chief executive of Clear Street, a prime brokerage and financial infrastructure firm, and he continues to serve on that company’s board. The Cresco Labs seat therefore adds to an existing board commitment rather than replacing one.
What the Cresco Labs Board Appointment Signals About U.S. Capital Access
The company was unusually direct about the reasoning. Board chairman Tom Manning tied the recruitment to a shifting federal environment in the United States and to the prospect of broader capital markets access for cannabis companies, saying Tilly “has spent his career building and governing the infrastructure that public markets run on.”
That framing matters because it is the central structural problem for the U.S. cannabis sector. Because cannabis remains federally controlled in the United States, plant-touching operators have historically been unable to list on major American exchanges, which is precisely why so many of them — Cresco included — ended up trading in Canada on the CSE and over the counter in the U.S. instead.
Putting a former exchange chief executive on the Audit Committee is the kind of preparation a company makes when it expects the listing and financing options available to it to change. Nothing in the announcement confirms a specific listing plan, a financing, or a timeline, and readers should not infer one.
How Manning and Tilly Framed the Move
Manning described the appointment as adding a perspective the board wants “as we prepare for the next stage of Cresco’s growth,” pointing to the strategic and financial opportunities he expects as U.S. capital markets access opens to companies like his.
Tilly, for his part, pointed at the operating business as the reason he said yes. He described Cresco as having built a leading branded portfolio in U.S. cannabis alongside a retail platform that “consistently outperforms its markets,” and said that foundation positions the company well as access to U.S. capital markets broadens.
Neither executive quantified those claims in the announcement, and the performance characterisations are the company’s own.
The Sunnyside Retail Network and the Brands Behind It
Cresco Labs positions itself as a consumer packaged goods business applied to cannabis — cultivation, production and branded distribution at national scale, paired with retail. Its brand portfolio includes Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi.
On the retail side, the company operates dispensaries nationally under the Sunnyside banner, with a stated focus on patient and consumer trust, education and convenience. It also runs year-round policy work, community outreach and its SEED initiative, which the company describes as covering economic opportunity, investment, workforce development and legislative engagement.
That combination — owned brands plus owned shelves — is the operating story an incoming audit committee member will be asked to oversee financially.
Why a CSE-Listed U.S. Operator Matters to Canadian Market Watchers
General market context: the Canadian Securities Exchange has for years served as the listing venue of choice for U.S. cannabis operators shut out of American exchanges. That has made Canadian market infrastructure — exchanges, transfer agents, custodians and the disclosure regime under Canadian securities legislation — a de facto host for a large part of the American industry’s public equity.
If U.S. capital markets access genuinely broadens, that arrangement is the thing most likely to be renegotiated, with implications for listing volumes and trading activity on this side of the border. Canadian investors reading this alongside the domestic picture will recognise the same theme running through the capital commitments announced at the Canada Investment Summit: where capital chooses to list and deploy is itself becoming a competitive question.
Financing conditions are the other variable. The direction of borrowing costs, shaped in part by the Bank of Canada’s decision to hold its policy rate with prime at 4.45%, continues to influence how expensive growth capital is for cross-border issuers of every size.
The Details Cresco Did Not Disclose
Several things worth knowing were left out of the announcement, and it is fair to name them rather than guess:
- Director compensation: Not specified in the announcement.
- Term or standing for election: Not mentioned — no annual meeting date was given.
- Audit Committee chair: Not mentioned; Tilly is described only as joining the committee.
- Other board changes: None disclosed. The board moves from seven to eight directors, indicating an addition rather than a replacement.
- Any specific listing or financing plan: Not mentioned.
A note on the language in the underlying announcement: it contains forward-looking statements about future events and objectives, including expectations around U.S. capital markets access. Those are the company’s beliefs, not confirmed outcomes, and the associated risk factors are set out in Cresco’s Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR. Nothing here is investment advice.
